Loading…

Terumo Corp4543.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Medical Specialties

Maker of medical devices: catheters, blood-management systems and infusion/hospital products.

≈ Japan's Becton Dickinson/Boston ScientificMomentum leader 85
Mkt cap
$24.0B
US dollars, full cap
Free float
91%
of shares outstanding
$/day
$102M
20-day average traded
Fwd P/E
27.8×
forward earnings
ROIC−WACC
+1.8 pp
WACC 7.2%
Hurdle
-4 pp
Req g minus delivered
Official | Implied
A- / AA-
agencies · bond market
Next earnings
84 days
10 Feb 2027
Close · JPY¥2,534
1D+1.0%
1W+0.7%
1M+8.3%
3M-5.2%
6M+31.8%
YTD+12.4%
1Y+1.5%
ATR %3.7%
52w lowhigh5.8% off high

What Terumo does

Maker of medical devices: catheters, blood-management systems and infusion/hospital products.

Sells single-use devices that hospitals and blood centers reorder, so revenue is repeat purchasing rather than one-off equipment. Overseas markets account for most of sales. It bought the US blood-technology business now called Terumo BCT in 2011, which gave it a large presence in blood processing.

In one line: Japan's Becton Dickinson/Boston Scientific.

Products and services

  • Cardiac and vascular devices (catheters, stents)
  • Blood and cell technologies (transfusion/apheresis)
  • Hospital care products (needles, infusion)

Customers

  • Hospitals/cath labs
  • Blood banks/transfusion centers
  • Healthcare distributors

Where it sits in the supply chain

  • Healthcare
  • Medical devices
  • Cardiac/vascular devices, blood…

What could go right

  • Aging-population cardiovascular procedure growth
  • Blood-management technology adoption

What could go wrong

  • Medical-device pricing/reimbursement pressure
  • Regulatory approval risk

Moat: narrow (IP / patents, regulatory licence, installed base). Long-standing regulatory approvals and hospital-purchasing relationships across catheter/blood-device lines.

Headquarters: Tokyo, Japan · Founded: 1921 · Employees: 31,185

Named competitors

Terumo at a glance

Size Terumo (4543.T) is a Japan Health Care company (Medical Specialties) with a market value of $24.0B, the 71st largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,534 on 18 Nov 2026.

Performance Over six months the shares gained 31.8%, against +26.0% for the median peer and -1.4% for the Japan market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 15.0% over the last twelve months (peer median +6.7%); the operating margin is 17.0% (peer median 19.3%).

Valuation It trades at 27.8× forward earnings against a peer median of 28.0× (10th cheapest of 20).

Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -4 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.8 points above its cost of capital (7.2% WACC).

Credit Terumo has 1 bond outstanding ($500M), rated A- by the agencies and trading like AA- at a weighted spread of 54 bp.

Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 1244543.T 111
Six months, rebased to 100: Terumo against the median of its 20 peers (local-currency closes).

Terumo financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥1.22T¥1.13T¥1.04T¥922B¥820B
Revenue growth—+9%+12%+12%—
Gross profit¥647B¥566B¥533B¥454B¥394B
EBITDA¥315B¥280B¥264B¥211B¥188B
Net income¥114B¥136B¥117B¥106B¥89.3B
Free cash flow¥199B¥146B¥142B¥85.6B¥64.8B
Capital expenditure¥100B¥102B¥82.4B¥78.8B¥72.2B
Total debt¥317B¥427B¥214B¥269B¥267B

Quarterly statements and history in the cockpit →

Terumo competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

+20%+40%+60%-10%0%+10%+20%DIMSTEWSTSTMNSRTSOONGHZBHDXCMILMN300760RVTYRMDMTDCOLO-BGEHC688271GKOSLENSKART4543.T6-month return →1-month return →
Up and to the right = strong over both horizons. Terumo is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×50×100×150×DIMSTEWSTSTMNSOONZBHDXCMALCGEHC688271GKOSLENSKART4543.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Terumo is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%DIMSTEWSTSTMNSRTSOONZBHDXCM300760RVTYMTDCOLO-BALCLENSKART4543.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Terumo is the large dot.

Terumo competitors and peer comparison

Head to head with its named competitors (4543.T vs BSX vs BDX vs ABT)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Terumo 4543.T$24.0B+32%+15%17%27.8×8.8%
Boston Scientific BSX$63.3B-23%+9%21%14.1×5.8%
Becton Dickinson BDX$58.9B+48%-7%16%16.3×-1.6%
Abbott Laboratories ABT$181B+18%+10%14%17.9×16.5%
Medtronic MDT$129B+30%+10%20%16.8×9.1%

How Terumo compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Terumo against its 20 peers (data as of 18 Nov 2026)
Measure4543.TPeer medianRank in peer set
1-month return+8.3%+6.1%9th highest of 21
6-month return+31.8%+26.0%9th highest of 21
Distance from 52-week high-5.8%-8.4%8th highest of 21
Revenue growth (TTM)+15.0%+6.7%5th highest of 21
Operating margin17.0%19.3%9th lowest of 21
Forward P/E27.8×28.0×10th cheapest of 20
Growth the price implies (Req g, 7 yrs)8.8%16.2%7th least demanding of 18
Growth delivered (Del g)+13.0%+8.3%4th highest of 18
Hurdle (Req g minus delivered)-4.2 pp+4.2 pp4th least demanding of 18
ROIC minus cost of capital+1.8 pp+3.2 pp9th lowest of 21
EV / EBITDA12.2×20.8×3rd cheapest of 17
Net debt / EBITDA0.0×1.2×4th least indebted of 17
Bond spread54 bp90 bptightest of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Terumo 4543.TJapan$24.0B+32%+15%17%27.8×8.8%+13.0%
Sartorius Stedim Biotech DIM.PAFrance$24.2B+32%+4%19%45.7×33.4%+9.2%
Steris STEUnited States$25.2B+21%+8%20%21.9×14.0%+13.8%
West Pharmaceutical Services WSTUnited States$28.1B+32%+13%23%40.2×25.8%+7.4%
Straumann STMN.SWSwitzerland$20.4B+20%+2%21%32.9×16.2%+12.8%
Sartorius SRT.DEGermany$19.9B+26%+4%18%43.0×25.6%+8.7%
Sonova SOON.SWSwitzerland$19.8B+40%-6%23%25.3×6.0%+6.7%
Guardant Health GHUnited States$19.6B+26%+42%-39%n/an/an/a
Zimmer Biomet ZBHUnited States$19.6B+21%+7%16%11.7×7.4%+3.2%
Dexcom DXCMUnited States$30.8B+16%+13%24%28.0×19.6%+19.3%
Illumina ILMNUnited States$31.8B+48%+6%21%35.2×27.2%+6.0%
Shenzhen Mindray Bio-Medical Electronics 300760.SZChina$33.6B+15%+5%28%27.3×1.0%+9.7%
Revvity RVTYUnited States$17.0B+61%+5%16%26.2×26.4%-5.5%
ResMed RMDUnited States$34.1B+16%+9%34%19.7×5.7%+12.1%
Mettler Toledo MTDUnited States$34.6B+60%+7%29%33.7×20.1%+5.5%
Coloplast A/S COLO-B.CODenmark$16.6B+24%+4%25%20.0×-2.1%+8.3%
Alcon ALC.SWSwitzerland$36.9B+18%+1%12%21.5×12.2%+6.1%
GE HealthCare GEHCUnited States$37.8B+30%+7%14%15.6×5.0%+3.7%
Shanghai United Imaging Healthcare 688271.SSChina$14.4B+4%+27%9%45.7×n/an/a
Glaukos GKOSUnited States$13.8B+62%+47%-9%161.5×n/an/a
Lenskart Solutions LENSKART.NSIndia$13.6B+49%+35%10%137.7×53.2%+33.5%

Terumo bonds and credit

Terumo has 1 bond outstanding with $500M face value. The agencies rate it A-; its bonds trade like AA-. Weighted yield 5.36%, a spread of 54 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Terumo's main competitors?
Named competitors: Boston Scientific (BSX), Becton Dickinson (BDX), Abbott (ABT), Medtronic (MDT). The cockpit's measured peer set (industry) also includes Sartorius Stedim Biotech (DIM.PA), Steris (STE), West Pharmaceutical Services (WST), Straumann (STMN.SW), Sartorius (SRT.DE), Sonova (SOON.SW).
Is Terumo expensive compared with its peers?
On forward p/e it trades at 27.8× against a peer median of 28.0×, 10th cheapest of 20 in its peer set. For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -4 pp: the price already allows for a slowdown.
How has Terumo stock performed?
Over six months to 18 Nov 2026 the shares returned +31.8% against +26.0% for the median peer; over one year +1.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.